Coinfection with Mycoplasma pneumoniae and Chlamydia pneumoniae in ruptured plaques associated with acute myocardial infarction;Co-infecção por Mycoplasma pneumoniae e Chlamydia pneumoniae em placas rotas associadas a infarto agudo do miocárdio

Arquivos Brasileiros de Cardiologia

Volumn 81, Issue 1, 2003, Pages 12-22

  Higuchi, Maria de Lourdes ^a   Reis, Marcia Martins ^a   Sambiase, Nádia Vieira ^a   Pinheiro Palomino, Suely Aparecida ^a   Castelli, Jussara Bianchi ^a   Gutierrez, Paulo Sampaio ^a   Aiello, Vera Demarchi ^a   Franchini Ramires, José Antonio ^a  

^a NONE

Author keywords

Acute myocardial infarction; Chlamydia pneumoniae; Mycoplasma pneumoniae

Indexed keywords

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL DIAMETER; CHAGAS DISEASE; CHLAMYDOPHILA PNEUMONIAE; CLINICAL ARTICLE; CORONARY ARTERY; DISEASE ASSOCIATION; FEMALE; HEART DILATATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MYCOPLASMA PNEUMONIAE;

EID: 0042429075     PISSN: 0066782X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0066-782x2003000900001     Document Type: Article

References (78)

1. van der Wal AC, Pieck JJ, de Boer OJ, et al. Recent activation of the plaque immune response in coronary lesions underlying acute coronary syndromes. Heart 1998;80:14-8.
2. Libby P, Geng YJ, Aikawa M et al. Macrophages and atherosclerotic plaque instability. Curr Opin Lipidol 1996;7:330-5.
3. Yasunobu Y, Hayashi K, Shingu T, Yamagata T, Kajiyama G, Kambe M. Coronary atherosclerosis and oxidative stress as reflected by autoantibodies against oxidized low-density lipoprotein and oxysterols. Atherosclerosis 2001;155:445-53.
4. Gobel H, van der Wal AC, Teeling P, van der Loos CM, Becker AE. Metallothionein in human atherosclerotic lesions: a scavenger mechanism for reactive oxygen species in the plaque? Virchows Arch 2000;437:528-33.
5. Wilcox JN, Smith KM, Schwartz S, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989;86:2839-43.
6. Marmur JD, Thiruvikraman SV, Fyfe SV, et al. The identification of tissue factor in human coronary atheroma. Circulation 1996;94:226-36.
7. Moreno PR, Bernardi VH, Lopez-Cuellar J, et al. Macrophages, smooth muscle cells and tissue factor in unstable angina: implications for cell mediated thrombogenicity in acute coronary syndromes. Circulation 1996;94:3090-7.
8. Mahony JB, Coombes BK. Chlamydia pneumoniae and atherosclerosis: does the evidence support a causal or contributory role? FEMS Microbiol Lett 2001;197:1-9.
9. Burian K, Kis Z, Virok D, et al. Independent and joint effects of antibodies to human heat-shock protein 60 and Chlamydia pneumoniae in the development of coronary atherosclerosis. Circulation 2001;103:1503-8.
10. Vink A, Poppen M, Schoveveld AH, et al. Distribution of Chlamydia pneumoniae in the human arterial system and its relation to the local amount of atherosclerosis within the individual. Circulation 2001;103:1613-7.
11. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat schock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998;98:300-7.
12. Kalayoglu MV, Indrawati, Morrison RP, Morrison SG, Yuan Y, Byrne GI. Chlamydial virulence determinants in atherogenesis: the role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions. J Infect Dis 2000;181(Suppl3):S483-9.
13. Thomas M, Wong Y, Ajaz M, Tsang V, Gallagher PJ, Ward ME. Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (Stary grading) of associated atherosclerotic plaque. Circulation 1999;99:2733-6.
14. Ericson K, Saldeen TG, Lindquist O, Pahlson C, Mehta JL. Relationship of C. pneumoniae infection to severity of human coronary atherosclerosis. Circulation 2000;101:2568-71.
15. Espinola-Klein C, Rupprecht HJ, Blanknenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002;105:15-21.
16. Wald NJ, Law MR, Morris JK, Zhou X, Wong Y, Ward ME. Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study. BMJ 2000;321:204-7.
17. Maass M, Jahn J, Gieffers J, Dalhoff K, Katus HA, Solbach W. Detection of Chlamydia pneumoniae within peripheral blood monocytes of patietns with unstable angina or myocardial infarction. J Infect Dis 2002;181(Suppl 3):S449-51.
18. Gurfinkel E, Bozovich G, Beck E, et al. Treatment with antibiotic roxithromycin in patients with acute non-Q-waved coronary syndromes. The final report of the ROXIS Study. Eur Heart J 1999;20:121-7.
19. Neumann F, Kastrati A, Miethke T, et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomized, double-blind, placebo-controlled trial. Lancet 2001;357:2085-9.
20. WIZARD study, presented in 51st American College Cardiology Scientific Session, Atlanta 2002.
21. Higuchi ML, Castelli JB, Aiello VD, et al. Great amount of chlamydia pneumoniae in ruptured plaque vessel segments at autopsy. A comparative study with stable plaques. Arq Bras Cardiol 2000;74:149-51.
22. Higuchi ML, Sambiase N, Palomino S, et al. Detection of Mycoplasma pneumoniae and Chlamydia pneumoniae in ruptured atherosclerotic plaques. Braz J Med Biol Res 2000;33:1023-6.
23. Razin S, Yogev D, Naot Y. Molecular Biology and pathogenicity of mycoplasmas. Microbiol Molec Biol Rev 1998;62:1094-156.
24. Bezerra HG, Higuchi ML, Gutierrez PS, et al. Atheromas that cause fatal thrombosis are usually larger and frequently accompanied by vessel enlargement. Cardiovasc Pathol 2001;10:189-96.
25. Higuchi ML, Gutierrez PS, Bezerra HG, et al. - Comparison between adventitial and intimal inflammation of ruptured and non-ruptured atherosclerotic plaques in human coronary arteries. Arq Bras Cardiol, 2002;79:20-24.
26. Reynolds ES. The use of lead citrate at high pH as an electron-opaque stain in electron microscope. J Cell Biol 1963;17:208-12.
27. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-8.
28. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50.
29. Ross R - Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340: 115-26.
30. French JE. Endothelial structure and function. In: Jones RJ, ed. Evolution of the aterosclerotic plaque. Chicago, Ill: University of Chicago Press; 1963:15-33.
31. Kao V, Wissler RW. A study of the immunohistochemical localization of serum lipoproteins and other plasma proteins in human atherosclerotic lesions. Exp Mol Pathol 1965;4:465-79.
32. Zilversmith DB. Cholesterol flux in atherosclerotic plaque. Ann N Y Acad Sci. 1968;149:710-24.
33. Ross R. Atherosclerosis: a problem of the biology of arterial wall cells and their interactions with blood components. Arteriosclerosis. 1981;1:293-311.
34. Libby P, Friedman GB, Salomon RN. Cytokines as modulators of cell proliferation in fibrotic diseases. Ann Rev Respir Dis. 1989;140:1114-17.
35. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991;64:5-15.
36. Fong IW. Antibiotics effects in a rabbit model of Chlamydia pneumoniae-induced atherosclerosis. J Infect Dis 2000;181(Suppl 3):S514-8.
37. Damy S, Higuchi ML, Timenetsky J, et al. Coinfection of laboratory rats with Mycoplasma pulmonis and Chlamydia pneumoniae. Contemp Top Lab Anim Sci 2003;42:52-6.
38. Baseman JB, Tully JG. Mycoplasmas: sophisticated reemerging and burdened by their notoriety. Emerging Inf Dis 1997;3:21-32.
39. Chambaud I, Wromblewski H, Blanchard A. Interactions between mycoplasma lipoproteins and the host immune syustem. Trends Microbiol 1999;7:493-9.
40. Baseman JB, Tully JB. Mycoplasmas: sophisticated, re-emerging, and burdened by their notoriety. Emerging Infect Dis. 1997;3:21-32.
41. Maniloff J, McElbaney RN, Finch LR, Baseman JB (ed.). 1992; Mycoplasmas: molecular biology and pathogenesis. American Society for Microbiology, Washington DC
42. Balse F, Fagetti L, Allegra L. Chlamydia pneumoniae detection in atherosclerotic plaques in Italy. J Infect Dis 2000;181(Suppl 3):S444-6.
43. Maraha B, Berg H, Scheffer GJ, et al. Correlation between detection methods of Chlamydia pneumoniae in atherosclerotic and non-atherosclerotic tissues. Diagn Microbiol Infect Dis 2001;39:139-43.
44. van der Wal AC, Becker AE, van der Loos CM, Tigges AJ, Das PK. Fibrous and lipid-rich atherosclerotic plaques are part of interchangeable morphologies related to inflammation: a concept. Cor Art Dis 1994;5:463-9.
45. Steinberg D. Antioxidants and atherosclerosis. A current assessment. Circulation. 1991;84:1420-5.
46. Fuster V, Gotto AM, Libby P, Loscalzo J, McGill H, Task Force I. Pathogenesis of coronary disease: The biologic role of risk factors. J Am Coll Cardiol 1996;27:964-1047.
47. Fuster V, Badimon JJ, Chesebro JH, Fallon JT. Plaque rupture, thrombosis, and therapeutic implications. Haemostasis 1996;26(Suppl4):269-84.
48. Berger M, Schroeder B, Daeschlein G, et al. Chlamydia pneumoniae DNA in non-coronary atherosclerotic plaques and circulating leukocytes. J Lab Clin Med 2000;136:194-200.
49. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloproxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 1001;158:879-91.
50. Rikitake Y, Kawashima S, Takeshita S, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001;154:87-96.
51. Fuhrman B, Aviram M. Flavonoids protect LDL from oxidation and attenuate atherosclerosis. Curr Opin Lipidol 2001;12:41-8.
52. Durak I, Kamaz M, Cimen MY, Buyukkocak U, Ozturk HS. Blood oxidant/antioxidant status of atherosclerotic patients. Int J Cardiol 2001;77:293-7.
53. Palinski W, Yĺa-Herttuala S, Rosenfeld ME, et al. Antisera and monoclonal antibodies for epitopes generated during the oxidative modification of low density lipoprotein. Arterioscler Thromb 1990;10:325-35.
54. Steinbrecher UP, Fisher M, Witztum JL, Curtiss LK. Immunogenicity of homologous low-density lipoprotein after methilation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. J Lipid Res. 1984;25:1109-16.
55. Almagor M, Kahane I, Yatziv S. Rote of superoxide anion in host cell injury induced by M. pneumoniae infection. A study in normal and trisomy 21 cells. J Clin Invest 1984;73:842-7.
56. 2 production by fermentative Mycoplasma spp. J Med Microbiol 1991;34:219-23.
57. Taylor RR, Mohan K, Miles RJ. Diversity of energy-yelding substrates and metabolism in avian mycoplasmas. Vet Microbiol 1996;51:291-304.
58. Ben-Menachem G, Himmelreich R, Herrmann R, Aharonowithz Y, Rottem S. The thiodoxin reductase system of mycoplasmas. Microbiology 1997;143:1933-40.
59. Almagor M, Kahane I, Gilon C, Yatziv S. Protective effects of glutathione redox cycle and vitamin E on cultured fibrobasts infected by Mycoplasma penumoniae. Infect Immun 1986;52:240-4.
60. Chocola J, Strosberg AD, Stanislawski M. Release of hydrogen peroxide from human T cell lines and normal lymphocytes co-infected with HIV-1 and mycoplasma. Free Radic Res 1995;23:197-212.
61. Blanchard A, Montagnier L. AIDS-associated mycoplasmas. Annu Rev Microbiol 1994;48:687-712.
62. Chambaud I, Wroblewski H, Blanchard A. Interactions between mycoplasma lipoproteins and the host immune system. Trends Microbiol 1999;7:493-9.
63. Faulkner CB, Simecka JW, Davidson MK, et al. Gene expression and production of TNFα, IL-1, IL-6 and IFN-γ in acute Mycoplasma pulmonis disease. Infect Immun 1995;63:4084-90.
64. Pietsch K, Ehlers S, Jacobs E. Cytokine gene expression in the lungs of BALB/c mice during primary and secondary intranasal infection with Mycoplasma pneumoniae. Microbiology 1994;140:2043-8.
65. Izutsu KT, Fatherazi S, Belton CM, Oda D, Cartwright FD, Kenny GE. Mycoplasma orale infection affects K+ and Cl-currents in the HSG salivary fland cell line. In Vitro Cell Dev Biol Anim 1996;32:361-5.
66. Matsui M, Kobayashi M, Mitsup Y. Elevation of endothelin biosynthesis in human endothelial cells with mycoplasma infection. In Vitro Cell Dev Biol Anim 1995;31:880-5.
67. Rawadi G, Roman-Roman S, Castedo M, et al. Effects of Mycoplasma fermentans on the myelomonocytic lineage. Different molecular entities with cytokine-inducing and cytocidal potential. J Immunol 1996;156:670-8.
68. Shibata K, Watanabe T. Mycoplasma fermentans enhances concavalin A-induced apoptosis of mouse splenic T cells. FEMS Immunol Med Microbiol 1997;17:103-9.
69. Sasaki Y, Cunha RA, Gougeon L, Montagnier L, Blanchard A. Mycoplasma penetrans cytopathic effects: an in vitro study using human peripheral blood mononuclear cells. IOM Lett. 1996;4:6-7.
70. Grau O, Slizewicz B, Tuppin P, et al. Association of Mycoplasma penetrans with human immunodeficiency virus infection. J Infect Dis 1995;172:672-81.
71. Lapidot Z, Naot Y. Immunohistochemical characterization of Mycoplasma pulmonis membrane mitogens. IOM Lett 1996;4:385.
72. Tsai S, Wear DJ, Shih JW, Lo SC. Mycoplasma and oncogenesis: persistent infection and multistage malignant transformation. Proc Natl Acad Sci 92:10197-201.
73. Fan T, Lu H, Hu H, et al. Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation. J Exp Med 1998;187(4):487-96.
74. Murry CE, Gipaya CT, Bartosek T, Benditt EP, Schwartz SM. Monoclonality of smooth muscle cells in human atherosclerosis. Am J Pathol 1997;151:697-705.
75. Schwartz SM, Majesky MW, Murry CE. The intima: development and monoclonal responses to injury. Atheroslcerosis 1995;118:S125-40.
76. Meijer A, van der Vliet JAQ, Roholl PJ, Gielis-Porper SK, de Vries A, Ossewaarde JM. Chlamydia pneumoniae in abdominal aortic aneurysms: abundance of membrane components in the absence of heat shock protein 60 and DNA. Arterioscler Thromb Vasc Biol 1999;19:2680-6.
77. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999;99:348-53.
78. Fong IW, Chiu B, Viira E, Jang D, Mahony JB. De Novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. Infect Immun 1999;67:6048-55.